// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























41730 Abstracts

Combined targeting of MET and PI3K improves efficacy in breast cancer models with concurrent MET/PI3K aberrations

Shuying Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Onartuzumab

Patient stratification and drug combination strategy based on drug response and genomic information from PDX clinical trials (PCTs)

Jingjing Jiang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH)

David Arguello - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Brain natriuretic peptide (BNP) as molecular marker for bladder, ovarian, and glioblastoma cancers

Cynthia Lee - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A new rabbit monoclonal antibody to FOXM1 for immuohistochemical assessment

Jackie K. Chan - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Immunofluorescence chromatographic assay of tumor cells in dried blood spot

Ming Zhao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Preservation of cells in blood and culture

Cecille Browne - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Performance assessment of highly sensitive NGS assay for TP53

Johannes Fredebohm - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

Chun Zhang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Functional analysis of discoidin domain receptor 2 mutation and expression in squamous cell lung cancer

Naomi Kobayashi-Watanabe - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Solid malignancies

dasatinib

Immunofluorescent digital slide technology to evaluate correlation between Glypican-3 expression and response to codrituzumab

Takayoshi Tanaka - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Codrituzumab

Sensitive detection of BRAF V600E mutation by bridged nucleic acid (BNA)-mediate real-time PCR assay

Xiaoyun Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Biochemical and cellular monitoring of the activity of the ecto-5-nucleotidase (CD73), a key cancer modulator using HTS-formatted bioluminescent technology

Said A. Goueli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Adenosine

A new, highly sensitive ALK antibody improves the screening of rearranged-ALK by IHC

Hsiangmin Lu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Crizotinib

Mitochondrial perturbations as a novel approach to personalized medicine

shruti bhatt - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Translational strategy for targeting MCL1 amplified tumors with CDK9 inhibitor

Ziping Yang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dinaciclib

Functional analysis of family with sequence similarity 83, member B in lung adenocarcinoma

Takumi Yamaura - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hypermethylation of GATA2 is validated as a marker of progression in non-muscle invasive bladder cancer

Kim E.M. van Kessel - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma

Heounjeong Go - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Circulating fibroblast growth factor 21 (FGF21) as diagnostic and prognostic biomarker in renal cancer

Maria Elena Knott - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

FGF-21

Copyright © 2026. QuantiNova All rights reserved